Form 4: ESSA Pharma Acquired: Director Sells Shares

ESSA Pharma Inc. director Franklin M. Berger reported the sale of all his common shares following the company's acquisition by Xeno Acquisition Corp. for cash and contingent value rights.

Summary

• ESSA Pharma Inc. was acquired by Xeno Acquisition Corp. on October 9, 2025.
• The acquisition was executed pursuant to a Business Combination Agreement dated July 13, 2025, as amended on September 23, 2025.
• Shareholders received approximately US$0.12 in cash for each common share.
• Shareholders also received one Contingent Value Right (CVR) for each common share, entitling them to receive up to approximately US$0.14 per CVR.
• Director Franklin M. Berger reported owning 0 common shares following the transaction, indicating his 784,404 shares were acquired as part of this transaction.

Sentiment

Score: 6

Explanation: The acquisition provides liquidity and potential upside for shareholders through CVRs, but also marks the end of the independent public entity, introducing some uncertainty regarding the CVR's ultimate value.

Positives

• Shareholders received immediate cash consideration of approximately US$0.12 per share.
• The inclusion of a Contingent Value Right (CVR) offers potential additional value of up to approximately US$0.14 per CVR.
• The transaction provides a clear exit strategy and liquidity for existing shareholders.

Negatives

• ESSA Pharma Inc. common shares are no longer publicly traded, removing future investment opportunities in the independent entity.
• The full value of the CVR (up to US$0.14) is contingent and not guaranteed, introducing uncertainty for shareholders.

Risks

• The value of the Contingent Value Rights (CVRs) is subject to future events and may not reach the maximum potential of US$0.14 per CVR.

Future Outlook

The filing primarily reports a completed acquisition transaction. The future outlook for former ESSA Pharma shareholders is tied to the realization of value from the Contingent Value Rights (CVRs), which are payable within specified periods following the close of the transaction.

Industry Context

This acquisition reflects ongoing consolidation within the biotechnology and pharmaceutical sectors, where smaller companies with promising assets are often acquired by larger entities seeking to expand their pipelines or market share. The use of CVRs is a common mechanism in such deals to bridge valuation gaps and share future upside potential with selling shareholders.

Stakeholder Impact

• Shareholders: Received cash and CVRs for their shares, providing liquidity and potential future value.

Next Steps

• Payment of Contingent Value Rights (CVRs) within specified periods following the transaction close.

Key Dates

Keywords

ESSA Pharma, EPIX, XenoTherapeutics, Xeno Acquisition Corp, XOMA Royalty, Business Combination, Acquisition, Merger, Form 4, Insider Transaction, Director, Share Sale, CVR, Contingent Value Right